Delayed emesis induced by moderately emetogenic chemotherapy: Do we need to treat all patients?

Ballatori, Enzo; Roila, Fausto; Tonato, Maurizio; Angelis, Verena De; Riva, Eleonora; Barbian, P.; Favero, A. Del; Basurto, C; Ciccarese, Giulia; Palladino, M. A.; Mosconi, Anna Maria; Anastasi, P.; Picciafuoco, M.; Campora, E; Chiara, Silvana; Cognetti, Francesco; Ferraresi, Virginia; Fabi, Alessandra; Tonachella, R; Cirulli, S.; Sabbatini, Roberto; Fédérico, Massimo; Trassoldati, A.; Silingardi, Vittorio; Ferrara, Arcispedale S. Anna; Donati, D.; Maestri, A; Malacarne, P; Ricci, S.; Antonuzzo, Andrea; Allegrini, Giacomo; Conte, Pier Franco; Salvati, Franco; Nunziati, F.; Antilli, A; Catalano, G.; Cascinu, Stefano; Costanzo, Francesco Di; Tagliaventi, M.; Zaniboni, Alberto; Meriggi, Fausto; Cortesi, Enrico; Ramponi, Sara; Locatelli, MC; D'Antona, Adelaide; Santoro, A; Zucchinelli, Patrizia; Mantellim, E.; Ferretti, G.; Boni, C.; Moretti, G; Scagliotti, G.; Daniele, O; Lissoni, Alfredo; Tateo, Saverio

doi:10.1023/a:1008229721099

Cited by 21 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increased incidence of acute nausea in the PALO group may affect the incidence of delayed nausea. This detail deserves consideration because good control of acute CINV leads to better control of delayed CINV [26][27][28]. However, due to the small study population, it was not possible to compare the incidence of delayed nausea between those who did not report acute CINV and those who experienced acute CINV.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of Palonosetron, 1-Day Dexamethasone, and Aprepitant in Patients Undergoing Carboplatin-Based Chemotherapy

Hayashi¹,

Shimokawa²,

Matsuo³

et al. 2023

Oncology

View full text Add to dashboard Cite

Introduction: Dexamethasone (DEX)-sparing strategy with 5-hydroxytryptamine-3 receptor antagonist (5HT3RA) and aprepitant (APR), as triplet antiemetic prophylaxis, is associated with poor control of delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving carboplatin (CBDCA)-based chemotherapy. This study aimed to evaluate whether using palonosetron (PALO) as a 5HT3RA provides superior control with CINV than first-generation (1st) 5HT3RA in triplet antiemetic prophylaxis with a DEX-sparing strategy. Methods: Pooled patient-level data from a nationwide, multicenter, and prospective observational study were analyzed to compare the incidence of CINV between patients administered PALO and 1st 5HT3RA in combination with 1-day DEX and APR. Results: No significant differences were observed in the incidence of CINV, pattern of CINV, or severity of nausea by type of 5HT3RA in triplet antiemetic prophylaxis with DEX-sparing strategy. In both groups, the incidence of nausea gradually increased from day 3, peaked on day 4 or 5, and then declined slowly. The visual analog scale scores in the delayed phase remained high throughout the 7-day observation period. Conclusion: Careful patient selection and symptom monitoring are needed when implementing the DEX-sparing strategy in triplet antiemetic prophylaxis for patients undergoing CBDCA-based chemotherapy. Furthermore, additional strategies may be needed to achieve better control of delayed CINV.

show abstract

Section: Discussionmentioning

confidence: 99%